BAKER HUGHES CLASS A (BKR)
Sector: Energy
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Energy
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for BKR
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| BKR | Former Chief Executive Officer; Nominee | 57 | ["Experienced industrial and energy-technology executive", "Led financial turnarounds and disciplined portfolio reshaping", "Led significant portfolio transformations in the European chemicals sector", "Guided Syensqo as a standalone public enterprise", "Comprehensive turnaround and portfolio repositioning at Solvay", "Restored profitability at Diversey"] | ["AC", "FC", "Finance", "Governance & Corporate Responsibility"] | 2026 |
Biography sourced from the proxy statement filing.
Independent Age: 57 Director Since: Nominee Other Public Directorships (Past Five Years): A.O. Smith Corporation (NYSE:AOS) (since 2016) Other Directorships and Affiliations: L Or al S.A. (OTCMKTS: LRLCF) (since 2020) Synesqo S.A. (OTCMKTS:SHBB) (2023-2026) Proposed Committees if Elected: Finance (Member) Governance & Corporate Responsibility (Member) Education: Chemical Engineering, Ecole d Application des Hauts Polym res de Strasbourg, France PhD, Macromolecular Physics and Chemistry, L Universit Louis Pasteur de Strasbourg, France Reasons for Nomination: Dr. Ilham Kadri is an experienced industrial and energy-technology executive who has led financial turnarounds and disciplined portfolio reshaping across multinational enterprises. Her scientific background and international leadership experience, combined with hands-on execution of strategic transactions and digital modernization, strengthen the Board s ability to advance Baker Hughes innovation and value-creation strategy. Key Skills and Qualifications: Dr. Kadri led one of the most significant portfolio transformations in the European chemicals sector, overseeing the strategic separation of Solvay into two independent public companies, Solvay and Syensqo. As Chief Executive Officer of Syensqo, she guided the company through its establishment as a standalone public enterprise, sharpening strategic focus, enforcing financial discipline and driving operational execution, while advancing digital capabilities across materials and industrial applications. Previously, as Chief Executive Officer of Solvay, Dr. Kadri led a comprehensive turnaround and portfolio repositioning, generating double-digit EBITDA growth, 18 consecutive quarters of positive free cash flow and balance-sheet deleveraging, while accelerating sustainability integration across the company s operating model. At Diversey, Dr. Kadri reoriented the portfolio toward higher-return industrial end markets, restored profitability and strengthened the company s operations as a standalone enterprise, culminating in a $3.2 billion divestiture to Bain Capital Private Equity. Career Highlights: Syensqo S.A. (OTCMKTS:SHBBF) Chief Executive Officer (2023-2025) Solvay S.A. (OTCMKTS:SLVYY) Chief Executive Officer (2019-2023) Diversey, Inc. (former Nasdaq:DSEY) President and Chief Executive Officer (2017-2019) Sealed Air Corporation (NYSE:SEE) President, Diversey Care division (2013-2017) Vice President (2013-2017) Dow Chemical Company (NYSE:DOW) General Manager, Dow Advanced Materials (2009-2012) Commercial Director, Dow Water & Process Solutions (2009-2012)